The evaluation of duloxetine effect for the parkinsonism and gait freezing
Not Applicable
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000016734
- Lead Sponsor
- Department of Neurology, Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The patinets adopted exclusion criteria 1, succidal tendency, severe depression. 2, Severe renal or liver dysfunction 3, hypoersensitivity for duloxetine. 4, Taking MAO-B inhibitor 5, complicated cognitive decline; MMSE under 23. 6, Schisophrenia or bipolar disorder 7, Personality disorders 8, eleavated ESR or CRP in blood examination. 9, ANA over 320 times, or Rheumatoid factor over 100 IU/ml. 10, comorbidity of epilepsy or seizure 11, dysuremia, galucoma. 12, alchol abuser 13, attending dcotor judge not to iclude this protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FOG-Q:freezing of gait questionnair UPDRS:Unified Parkinson's Disease Rating Scale H & Y; Hoehn and Yahr stage HDR-S:Hamilton Depression Rating Scale Beck Score QIDS-J; Quick Inventory of Depressive Symptomatology HDS-R; revised Hasegawa's dementia scale MMSE; Mini-mental scale examination VAS; Visual Analog Scale FRS; Face rating scale WPI; Widespread pain index; from Fibromyalgia diagnostic criteria, ACR2010
- Secondary Outcome Measures
Name Time Method